275 related articles for article (PubMed ID: 29045845)
1. Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.
Li Y; Sahni N; Pancsa R; McGrail DJ; Xu J; Hua X; Coulombe-Huntington J; Ryan M; Tychhon B; Sudhakar D; Hu L; Tyers M; Jiang X; Lin SY; Babu MM; Yi S
Cell Rep; 2017 Oct; 21(3):798-812. PubMed ID: 29045845
[TBL] [Abstract][Full Text] [Related]
2. The Functional Impact of Alternative Splicing in Cancer.
Climente-González H; Porta-Pardo E; Godzik A; Eyras E
Cell Rep; 2017 Aug; 20(9):2215-2226. PubMed ID: 28854369
[TBL] [Abstract][Full Text] [Related]
3. e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks.
Li Y; Burgman B; Khatri IS; Pentaparthi SR; Su Z; McGrail DJ; Li Y; Wu E; Eckhardt SG; Sahni N; Yi SS
Nucleic Acids Res; 2021 Jan; 49(1):e2. PubMed ID: 33211847
[TBL] [Abstract][Full Text] [Related]
4. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
5. Aberrant alternative splicing in breast cancer.
Yang Q; Zhao J; Zhang W; Chen D; Wang Y
J Mol Cell Biol; 2019 Oct; 11(10):920-929. PubMed ID: 31065692
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing: an emerging topic in molecular and clinical oncology.
Pajares MJ; Ezponda T; Catena R; Calvo A; Pio R; Montuenga LM
Lancet Oncol; 2007 Apr; 8(4):349-57. PubMed ID: 17395108
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer.
Lo A; McSharry M; Berger AH
BMC Cancer; 2022 Dec; 22(1):1315. PubMed ID: 36522653
[TBL] [Abstract][Full Text] [Related]
9. Systematic analysis of survival-associated alternative splicing signatures in clear cell renal cell carcinoma.
Chen T; Zheng W; Chen J; Lin S; Zou Z; Li X; Tan Z
J Cell Biochem; 2020 Oct; 121(10):4074-4084. PubMed ID: 31886566
[TBL] [Abstract][Full Text] [Related]
10. Understanding human DNA variants affecting pre-mRNA splicing in the NGS era.
Dufner-Almeida LG; do Carmo RT; Masotti C; Haddad LA
Adv Genet; 2019; 103():39-90. PubMed ID: 30904096
[TBL] [Abstract][Full Text] [Related]
11. Alternative splicing and biological heterogeneity in prostate cancer.
Rajan P; Elliott DJ; Robson CN; Leung HY
Nat Rev Urol; 2009 Aug; 6(8):454-60. PubMed ID: 19657379
[TBL] [Abstract][Full Text] [Related]
12. LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations.
Li Y; Li L; Wang Z; Pan T; Sahni N; Jin X; Wang G; Li J; Zheng X; Zhang Y; Xu J; Yi S; Li X
Nucleic Acids Res; 2018 Feb; 46(3):1113-1123. PubMed ID: 29325141
[TBL] [Abstract][Full Text] [Related]
13. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer.
Sebestyén E; Zawisza M; Eyras E
Nucleic Acids Res; 2015 Feb; 43(3):1345-56. PubMed ID: 25578962
[TBL] [Abstract][Full Text] [Related]
14. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
15. Diagnostics of pathogenic splicing mutations: does bioinformatics cover all bases?
Hartmann L; Theiss S; Niederacher D; Schaal H
Front Biosci; 2008 May; 13():3252-72. PubMed ID: 18508431
[TBL] [Abstract][Full Text] [Related]
16. Entropy measures quantify global splicing disorders in cancer.
Ritchie W; Granjeaud S; Puthier D; Gautheret D
PLoS Comput Biol; 2008 Mar; 4(3):e1000011. PubMed ID: 18369415
[TBL] [Abstract][Full Text] [Related]
17. Profiles of alternative splicing in colorectal cancer and their clinical significance: A study based on large-scale sequencing data.
Xiong Y; Deng Y; Wang K; Zhou H; Zheng X; Si L; Fu Z
EBioMedicine; 2018 Oct; 36():183-195. PubMed ID: 30243491
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
19. Transcription Factors in Cancer: When Alternative Splicing Determines Opposite Cell Fates.
Belluti S; Rigillo G; Imbriano C
Cells; 2020 Mar; 9(3):. PubMed ID: 32244895
[TBL] [Abstract][Full Text] [Related]
20. Roles and mechanisms of alternative splicing in cancer - implications for care.
Bonnal SC; López-Oreja I; Valcárcel J
Nat Rev Clin Oncol; 2020 Aug; 17(8):457-474. PubMed ID: 32303702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
